Novel antibody–antibiotic conjugate eliminates intracellular S. aureus

By S. Lehar, Thomas H. Pillow, M. Xu, Leanna R Staben, Kimberly K. Kajihara, R. Vandlen, Laura DePalatis, H. Raab, W. Hazenbos, J. Morisaki and 22 more. 2015

737 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Infectious Diseases, Molecular Medicine

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. M. Huemer
2. M. Otto
3. S. Brugger
4. Annelies S. Zinkernagel
5. P. Kubes
6. Srikanth Mairpady Shambat

In Infectious Diseases

1. Y. Taur
2. M. Huemer
3. M. Otto
4. S. Brugger
5. Eric G. Pamer
6. David L. Paterson
7. Annelies S. Zinkernagel
8. P. Kubes

In Molecular Medicine

1. M. Huemer
2. S. Brugger
3. David L. Paterson
4. Annelies S. Zinkernagel
5. Srikanth Mairpady Shambat

Citations in the corpus

• Multidrug evolutionary strategies to reverse antibiotic resistance (2016, positive): “Several complementary strategies for evolutionarily robust bacterial inhibition have been suggested, including suppression of virulence (21–23), persistence (24), and quorum sensing (25, 26), as well as novel targeting strategies to allow higher effective doses (27); however, they are outside the sc”
• Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. (2016, background): “In this study, rifalogue was conjugated to an S. aureus-specific antibody via a cleavable bridge such that opsonized MRSA, once phagocytosed, could be effectively killed by the protease-liberated antibiotic.”
• Naïve Human Antibody Libraries for Infectious Diseases (2018, background): “This conjugate was able to kill S. aureus inside human macrophages, endothelial and epithelial cell lines [202] .”
• Identification and treatment of the Staphylococcus aureus reservoir in vivo (2016, positive): “In fact, it was recently shown that MRSA placed inside cultured cells can survive intracellularly when those cultured cells were injected into mice, and required expensive antibody-based immunotherapy to be eradicated (Lehar et al., 2015).”
• Antibiotic resistance and persistence—Implications for human health and treatment perspectives (2020, positive): “In addition, intracellularly residing S. aureus (Dziewanowska et al , 1999; Jevon et al , 1999; Fraunholz & Sinha, 2012; Lehar et al , 2015) are protected from vancomycin and may be another reason for vancomycin treatment failure.”
• Antimicrobial Resistance in ESKAPE Pathogens (2020, background): “Such a scenario was recently illustrated by Lehar and colleagues, who showed that, compared to extracellular planktonic bacteria, intracellular MRSA isolates exhibit a 100-fold increase in the vancomycin MIC, as well as an enhanced propensity for systemic dissemination in an antibiotic-treated mouse”